Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ARMO, Backed by China Investors, Completes $128 Million IPO in US

publication date: Jan 26, 2018

ARMO BioSciences, a Bay Area immuno-oncology company, completed a $128 million IPO on the Nasdaq exchange. The shares rose 75% on the first day to close at $29.74. In its Series C-1 funding, completed in August 2017, ARMO raised $67 million led by China investor Qiming Ventures, and joined by new China investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments. ARMO's lead molecule is AM0010, a pegylated form of Interleukin-10, which is currently in Phase III trials as an adjunct to FOLFOX and in Phase I trials as a single agent. More details....

Stock Symbol: (NSDQ: ARMO)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China